Who
H. Lawrence Remmel
Director
Company insider
Files Form 4 as: Director, Atossa Therapeutics.
In numbers
- Trades disclosed
- 21
- Buys
- 5
- Sells
- 0
- Bought
- $33K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 8 Jan 2013
- Last trade
- 12 May 2026
- Last filed
- 14 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 May 2026filed 14 May 2026 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 15 May 2025filed 16 May 2025 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 26 Mar 2025filed 28 Mar 2025 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Bought | $7,00010,000 at $0.70 | filing |
| 27 Jun 2024filed 1 Jul 2024 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 4 May 2023filed 5 May 2023 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 13 May 2022filed 16 May 2022 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 14 May 2021filed 18 May 2021 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 15 May 2020filed 19 May 2020 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 17 May 2019filed 21 May 2019 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 27 Jun 2018filed 29 Jun 2018 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 24 May 2017filed 26 May 2017 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —57,685 at $0.00 | filing |
| 17 Apr 2017filed 18 Apr 2017 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Bought | $1,5752,500 at $0.63 | filing |
| 18 May 2016filed 19 May 2016 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —132,634 at $0.00 | filing |
| 1 Apr 2016filed 4 Apr 2016 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Bought | $4951,500 at $0.33 | filing |
| 12 Jun 2015filed 15 Jun 2015 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Bought | $7,0205,400 at $1.30 | filing |
| 12 May 2015filed 14 May 2015 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 6 May 2014filed 8 May 2014 | ATOS Atossa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 8 Jan 2013filed 9 Jan 2013 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Bought | $1,640400 at $4.10 | filing |
| 8 Jan 2013filed 9 Jan 2013 | ATOS Atossa TherapeuticsBiotechnology | SEC FORM 4 Bought | $6,7201,600 at $4.20 | filing |
News
No headline names them, or the companies they trade most, lately.